So, by now they are complementary, so in patients where you really wanted to state that they are MRD negative after therapy you have to use both; so one bone marrow technique either NGS or NGF and PAT or [inaudible] MRI outside the bone marrow. Of course, if you find the positivity in the bone marrow you may not go for a PET CT because you are already aware that the patient is MRD positive, but if you want really to state a negative status you have to look at both because as I said they are complementary...
So, by now they are complementary, so in patients where you really wanted to state that they are MRD negative after therapy you have to use both; so one bone marrow technique either NGS or NGF and PAT or [inaudible] MRI outside the bone marrow. Of course, if you find the positivity in the bone marrow you may not go for a PET CT because you are already aware that the patient is MRD positive, but if you want really to state a negative status you have to look at both because as I said they are complementary. Maybe in the future circulating DNA and liquid biopsy may play a role but we don’t have any answer by now.
The job that we did by now is regarding FDG, PET CT. We use for the first time they don’t build score criteria that are largely in news for lymphomas and we were able to identify that the score for the reference of the liver is the most representative of the outcomes of patients so what we proposed with this prospective joint analysis is to use the liver as a reference for positivity or negativity after therapy, so we believe that this is very important for pay for people in clinical practice.